ITRM Earnings Prediction
The chart below shows how ITRM performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ITRM sees a -0.93% change in stock price 10 days leading up to the earnings, and a +7.91% change 10 days following the report. On the earnings day itself, the stock moves by +2.51%. This data can give you a slight idea of what to expect for the next quarter's release.
ITRM Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.25
-73.40%
-16.67%
No Data Available
ITRM Earnings Analysis
Iterum Therapeutics PLC Corporation (ITRM.O) Earnings Conference Call
Positive
Orlymba FDA Approval: FDA approval received for Orlymba, the first and only oral penem approved in the U.S., addressing a significant unmet need in the uncomplicated urinary tract infection market.
Market Entry Opportunity: Orlymba is projected to enter a market generating approximately 40 million prescriptions annually, indicating a substantial revenue opportunity.
Improved Financial Performance: Non-GAAP net loss decreased by $7.6 million in Q4 2024 compared to Q4 2023, reflecting improved financial performance and cost management.
Operating Expenses Reduction: Total operating expenses reduced to $3.7 million in Q4 2024 from $11.4 million in Q4 2023, showcasing effective cost control measures.
Financial Stability Assurance: Cash and cash equivalents at $24.1 million as of December 2024, expected to fund operations into the second half of 2025, ensuring financial stability.
Negative
Operating Expenses Increase: Total operating expenses increased to $18,700,000 for the full year 2024, compared to $47,500,000 in 2023, indicating a significant rise in costs despite a decrease in R&D expenses.
Quarterly Net Loss Comparison: Net loss on a US GAAP basis was $6,600,000 for the fourth quarter of 2024, compared to a net loss of $10,700,000 in the same quarter of 2023, reflecting ongoing financial challenges.
Rising Administrative Costs: General and administrative costs rose to $8,000,000 for the full year 2024, up from $7,500,000 in 2023, primarily due to higher legal fees, indicating increased operational burdens.
Regulatory Payment Deferral: A regulatory milestone payment of $20,000,000 to Pfizer was deferred for two years, accruing interest at an annual rate of 8%, which could strain future cash flows and financial stability.
Cash Reserves Concerns: Cash and cash equivalents were reported at $24,100,000 as of December 2024, with expectations to fund operations only into the second half of 2025, raising concerns about long-term viability.
ITRM FAQs
How does ITRM typically perform around its earnings report dates?
Is Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ITRM Earning Call Sentiment
Earnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surges
ITRM.O
0%Positive
The earnings call highlights significant risks, including going concern issues, capital raising challenges, and uncertainties about market acceptance. Despite reduced operating expenses and net losses, the company's financial health remains precarious due to a deferred $20 million payment to Pfizer accruing interest. The lack of clear guidance on strategic partnerships further exacerbates concerns. The Q&A section reveals management's evasiveness, which may increase investor apprehension. Given these factors, the stock price is likely to face a negative reaction over the next two weeks.
